高流量鼻导管治疗儿童毛细支气管炎:系统综述与荟萃分析
该系统综述纳入9项随机对照试验共2121例毛细支气管炎患儿,比较经鼻高流量氧疗(HFNC)与其他氧疗方式的效果与安全性;HFNC与标准氧疗(SOT)及经鼻持续气道正压(nCPAP)在住院时长、氧疗时长、转入重症监护、插管率、呼吸频率、SpO2及不良事件方面均无显著差异;HFNC较SOT显著降低治疗失败率,但较nCPAP显著增加治疗失败率。
要点
- HFNC作为初始呼吸管理是安全的,但与SOT或nCPAP相比未见明确获益优势。
- HFNC较SOT显著降低治疗失败率(RR 0.50,95%CI 0.40–0.62,p<0.01)。
- HFNC较nCPAP显著增加治疗失败率(RR 1.61,95%CI 1.06–2.42,p=0.02)。
核心结论
- 该系统综述提示HFNC作为初始呼吸管理是安全的,但证据仍不足以显示其较SOT或nCPAP对毛细支气管炎患儿有获益。
研究设计与样本
- 检索6个电子数据库(包括PubMed、EMBASE、Cochrane Central Register of Controlled Trials、中国知网、维普、万方)自建库至2018年6月1日,纳入比较HFNC与其他氧疗方式的随机对照试验。
- 共纳入9项随机对照试验,2121例毛细支气管炎患儿。
主要发现
- HFNC组与SOT组及nCPAP组在住院时长、氧疗时长、转入重症监护室、插管发生率、呼吸频率、SpO2及不良事件方面均无显著差异。
- HFNC组较SOT组治疗失败发生率显著降低(RR 0.50,95%CI 0.40–0.62,p<0.01)。
- HFNC组较nCPAP组治疗失败发生率显著增加(RR 1.61,95%CI 1.06–2.42,p=0.02)。
- 亚组分析中,在低收入和中等收入国家,HFNC组较SOT组住院时长显著缩短。
临床怎么用
- HFNC可作为毛细支气管炎患儿安全的初始呼吸管理选择,但现有证据未显示其较SOT或nCPAP具有明确临床获益优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To review the effects and safety of high-flow nasal cannula (HFNC) for bronchiolitis. METHODS: Six electronic databases including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, CQ VIP Database and Wanfang Data were searched from their inception to 1 June 2018. Randomised controlled trials (RCTs) which investigated the effects of HFNC versus other forms of oxygen therapies for bronchiolitis were included. RESULTS: Nine RCTs with 2121 children met the eligibility criteria. There was no significant difference in length of stay in hospital (LOS), length of oxygen supplementation (LOO), transfer to intensive care unit, incidence of intubation, respiratory rate, SpO2 and adverse events in HFNC group compared with standard oxygen therapy (SOT) and nasal continuous positive airway pressure (nCPAP) groups. A significant reduction of the incidence of treatment failure (risk ratio (RR) 0.50, 95% CI 0.40 to 0.62, p<0.01) was observed in HFNC group compared with SOT group, but there was a significant increase of the incidence of treatment failure (RR 1.61, 95% CI 1.06 to 2.42, p0.02) in HFNC group compared with nCPAP group. In subgroup analysis, LOS was significantly decreased in HFNC group compared with SOT group in low-income and middle-income countries. CONCLUSION: The systematic review suggests HFNC is safe as an initial respiratory management, but the evidence is still lacking to show benefits for children with bronchiolitis compared with SOT or nCPAP.
引用
- Lin J, Zhang Y, Xiong L, et al. High-flow nasal cannula therapy for children with bronchiolitis: a systematic review and meta-analysis. Arch Dis Child. 2019. PMID: 30655267. doi:10.1136/archdischild-2018-315846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。